BindingDB logo
myBDB logout

117 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
26653735 81 Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.EBI Pfizer Inc.
26753813 22 Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.EBI University of Minnesota
26638045 58 Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.EBI UiT The Arctic University of Norway
26288689 37 Discovery of Potent and Selective Inhibitors for ADAMTS-4 through DNA-Encoded Library Technology (ELT).EBI GlaxoSmithKline
26192023 71 SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.EBI £Florida Atlantic University
25264600 64 Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.EBI Takeda Pharmaceutical Company Limited
25415648 63 Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.EBI Eli Lilly and Company
25192810 66 Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1 binding site.EBI Takeda Pharmaceutical Company Ltd
24735644 19 Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid- hydrolysis.EBI INSERM
24316668 34 Discovery of a benzimidazole series of ADAMTS-5 (aggrecanase-2) inhibitors by scaffold hopping.EBI Asahi Kasei Pharma Corporation
24044937 59 Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group.EBI INSERM
24044434 71 Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.EBI Università di Pisa
23453070 42 A series of thiazole derivatives bearing thiazolidin-4-one as non-competitive ADAMTS-5 (aggrecanase-2) inhibitors.EBI Asahi Kasei Pharma Corporation
22891645 83 Discovery of highly potent and selective small molecule ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded library technology (ELT).EBI GlaxoSmithKline
22175799 22 Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.EBI Alantos Pharmaceuticals AG
19715320 87 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI University of Florida
19095454 63 Current perspective of TACE inhibitors: a review.EBI The M. S. University of Baroda
18257543 16 Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.EBI The Hebrew University of Jerusalem
18061445 103 Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Research and Development
18032037 14 Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors.EBI Bristol-Myers Squibb Company
17188861 12 A molecular modeling analysis of novel non-hydroxamate inhibitors of TACE.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12773042 195 Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.EBI Wyeth Research
12773041 119 Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.EBI Wyeth Research
11831904 172 New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.EBI Nippon Organon K.K.
11472217 157 Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.EBI DuPont Pharmaceuticals Company
10669559 180 Protease inhibitors: current status and future prospects.EBI University of Queensland
11677139 88 The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.EBI Wyeth-Ayerst Research
11206468 24 Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.EBI Wyeth-Ayerst Research
11206467 44 The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.EBI Wyeth-Ayerst Research
11514167 88 The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.EBI Wyeth-Ayerst Research
22175825 19 Potent inhibitors of LpxC for the treatment of Gram-negative infections.EBI Pfizer Inc.
22017477 35 Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.EBI Instituto Superior T£cnico
21963348 7 Synthesis, preliminary biological evaluation and molecular modeling of some new heterocyclic inhibitors of TACE.EBI Sun Pharma Advanced Research Company Ltd
20638281 56 Structure and activity relationships of tartrate-based TACE inhibitors.EBI Merck Research Laboratories
21458257 87 2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.EBI Merck Research Laboratories
21417219 179 Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.EBI Central Pharmaceutical Research Institute
21300546 129 The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.EBI AstraZeneca
21078557 34 Structure based optimization of chromen-based TNF-a converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study.EBI Yonsei University
21106451 39 Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.EBI Merck Research Laboratories
20663669 36 Biaryl substituted hydantoin compounds as TACE inhibitors.EBI Merck Research Laboratories
20180536 128 Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.EBI Universit£ di Pisa
20172725 49 Discovery and SAR of hydantoin TACE inhibitors.EBI Merck Research Laboratories
19767207 17 Synthesis and SAR of 2-phenyl-1-sulfonylaminocyclopropane carboxylates as ADAMTS-5 (Aggrecanase-2) inhibitors.EBI Central Pharmaceutical Research Institute
20022498 71 The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.EBI Schering-Plough Research Institute Cambridge
20005097 58 Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.EBI Pfizer Inc.
19908842 84 Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.EBI National Human Genome Research Institute
19703773 63 The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.EBI GSK Medicines Research Centre
19725580 93 Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.EBI Wyeth Research
19606871 124 N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.EBI Universit£ di Pisa
18835710 69 Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.EBI Schering Plough Research Institute
19410464 71 Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.EBI Wyeth Research
19053764 101 Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.EBI Instituto Superior Técnico
18790648 317 Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.EBI University of Athens
17936631 25 Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.EBI Yonsei University
17576061 132 Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17531482 67 Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors.EBI Wyeth Research
17368021 55 Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17276676 112 A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17188863 107 Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17064892 123 Identification of potent and selective TACE inhibitors via the S1 pocket.EBI Wyeth Research
17027261 153 Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16723229 108 Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.EBI Wyeth Research
16516469 39 A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors.EBI Novartis Institutes for BioMedical Research
16516466 175 Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16473009 23 Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16426848 80 Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.EBI Wyeth Research
16289878 35 Conversion of potent MMP inhibitors into selective TACE inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16153831 87 Synthesis and SAR of highly selective MMP-13 inhibitors.EBI Wyeth Research
16084720 83 Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.EBI Wyeth Research
15953722 56 Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.EBI Pfizer Global Research and Development
15911259 49 Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13.EBI Pfizer Global Research and Development Groton Laboratories
15908214 95 Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15745814 75 Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors.EBI Wyeth Research
15686921 55 Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).EBI Pharmaceutical Research Institute
15566296 142 Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.EBI Wyeth Research
15546732 11 Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors.EBI Department of Life Science and National Research Laboratory of Proteolysis
15357971 228 Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15261259 48 Benzodiazepine inhibitors of the MMPs and TACE. Part 2.EBI Wyeth Research
15125955 84 Reverse hydroxamate-based selective TACE inhibitors.EBI Kaken Pharmaceutical Co., Ltd
15055993 30 Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.EBI Hokkaido Collaboration Center N-21
15006405 20 Synthesis and biological activity of selective azasugar-based TACE inhibitors.EBI Organon K.K.
14643313 129 Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
14643312 39 Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12951101 79 Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors.EBI Pfizer Global Research and Development
12877590 28 A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.EBI Pfizer Global Research and Development
12873518 81 Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.EBI Wyeth Research
12873505 20 Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.EBI Hokkaido Collaboration Center
12873504 36 Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.EBI Hokkaido Collaboration Center
12781190 110 Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12781187 15 Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Organon K.K.
12723945 167 Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12668018 138 Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.EBI Wyeth-Ayerst Research
12408705 73 Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.EBI Bristol-Myers Squibb Company
12270165 80 Benzodiazepine inhibitors of the MMPs and TACE.EBI Wyeth Research
11992783 78 Synthesis and biological activity of selective pipecolic acid-based TNF-alpha converting enzyme (TACE) inhibitors.EBI Pfizer Global Research and Development
11934588 69 Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.EBI Wyeth-Ayerst Research
11934587 19 Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.EBI Wyeth-Ayerst Research
11831905 33 New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.EBI Organon K.K.
11708926 84 Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI GlaxoSmithKline
11677124 67 Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.EBI Abbott Laboratories
11585440 76 Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.EBI DuPont Pharmaceuticals Company
11514157 48 N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.EBI GlaxoSmithKline Research and Development
10579851 151 New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.EBI Centre de Recherches
21406033 4 The evaluation of inhibitive effectiveness of the tumour necrosis factor-a converting enzyme selective inhibitors by HPLC.BDB Huazhong University of Science and Technology
15081893 29 Inhibition of fucosyltransferase VII by gallic acid and its derivatives.BDB Schering Plough Research Institute
19464885 63 Synthesis and activity of quinolinylmethyl P1' alpha-sulfone piperidine hydroxamate inhibitors of TACE.BDB Wyeth Research
18234496 12 Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).BDB Bristol-Myers Squibb Company
18242982 38 Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.BDB Bristol-Myers Squibb Company
18282708 80 Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents.BDB Bristol-Myers Squibb Company
17606376 51 Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.BDB Wyeth Research
14718605 8 Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.BDB Wyeth Research